AIM Delisting and Admission to the Standard Listing Segment of Main Market

AIM Delisting and Admission to the Standard Listing Segment of Main Market
Tiziana announces appointment of Dr Neil Graham MBBS, MD, MPH as Chief Medical Officer
NEW YORK and LONDON – 11 January 2021 (GLOBE NEWSWIRE) – Tiziana Life Sciences plc (NASDAQ: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative
Tiziana announces completion of the clinical trial with nasally administered Foralumab, its proprietary fully human anti-CD3 monoclonal antibody, for the treatment of COVID-19 patients in Brazil
Share Talk is proud to be hosting a Webinar with Amur Minerals on Wednesday, November 25, 2020 · 04:00:00 PM · London Time.
Phase 1b/2 Clinical Trial – Crohn’s Disease
Tiziana Announces Initiation of Clinical Trial for COVID-19 Patients in Brazil with Nasally Administered Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody
After investing heavily in our RNS delivery infrastructure over the last two years we are super proud to announce on our 150th weekly market issue that our tests have shown
London, New York, 26 October 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation
London, New York, 21 October 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation
At the General Meeting of the Company held at 11.00 a.m. on 2 October 2020, both of the resolutions were duly passed.